Radiosurgery for metastatic brain tumors.
Stereotactic radiosurgery (SRS) precisely delivers high-dose radiation to a small target (usually less than 3-4 cm in diameter), in a single session with steep dose-fall, employing various radiation methods. SRS provides good tumor control for small brain metastases from various primary cancers, with minimal untoward effects on surrounding normal brain. This excellent tumor control prevents neurological death and maintains good activity of daily life. Although surgery with whole-brain radiation therapy (WBRT) remains an important option for patients with a solitary brain metastasis, SRS with or without WBRT should be considered in patients with a limited number of small tumors and a good prognosis. Many reports, as well as both retrospective and prospective reviews, have shown WBRT before or after SRS to improve local control and reduce new distant lesion emergence. However, upfront WBRT does not improve survival. There are two major delivery techniques, Gamma Knife (GK; Elekta AB, Stockholm, Sweden) SRS and linear accelerator (LINIAC)-based SRS. They are based on quite different concepts, and have different techniques and clinical applications. These differences complicate the discussion of the limitations of and indications for SRS and the necessity for prophylactic WBRT. This review discusses numerous aspects of SRS, its value as compared with other treatment modalities, the necessity for prophylactic WBRT with SRS, the limitations of and indications for SRS, and the difference between GK and LINIAC SRS, based on the literature and our experience, and proposes a new strategy for the treatment of brain metastases in view of the available clinical data and experience.
Serizawa
Toru
T
Tsukiji Neurological Clinic, Tokyo Gamma Unit Center, 1-9-9 Tsukiji, Chuo-ku, Tokyo, Japan. gamma-knife.serizawa@nifty.com
D001932:Brain Neoplasms / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D016371:Cranial Irradiation; D019317:Evidence-Based Medicine; D006801:Humans; D016634:Radiosurgery / Q000009:adverse effects / Q000295:instrumentation; D018714:Radiotherapy, Adjuvant; D016896:Treatment Outcome
Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1492-8
17276617
Lancet. 2004 May 22;363(9422):1665-72
15158627
J Neurosurg. 2008 Dec;109 Suppl:118-21
19123897
Ann Surg Oncol. 1994 Mar;1(2):169-78
7834443
Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):549-58
10078636
Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):445-54
9308949
Technol Cancer Res Treat. 2007 Jun;6(3):153-60
17535022
Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):452-64
12957257
Cancer J. 2000 Mar-Apr;6(2):88-92
11069225
Radiother Oncol. 2000 Nov;57(2):207-13
11054525
Int J Radiat Oncol Biol Phys. 1992;24(4):619-25
1429083
Neurosurgery. 2005 May;56(5):936-45; discussion 936-45
15854241
N Engl J Med. 1990 Feb 22;322(8):494-500
2405271
Future Oncol. 2007 Feb;3(1):95-102
17280506
Neurosurgery. 2007 Feb;60(2):277-83; discussion 283-4
17290178
J Neurosurg. 1999 Jul;91(1):35-43
10389878
Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8
10802351
Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):527-32
12062593
J Clin Oncol. 2005 Dec 1;23(34):8870-6
16314647
J Neurosurg. 2005 Jan;102 Suppl:147-50
15662799
JAMA. 2006 Jun 7;295(21):2483-91
16757720
J Neurosurg. 2005 Jan;102 Suppl:128-33
15662795
Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):519-26
12062592
J Neurosurg. 2002 Dec;97(5 Suppl):499-506
12507085
J Neurosurg. 2002 Dec;97(6):1276-81
12507123
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
9128946
Acta Oncol. 1999;38(2):165-9
10227437
Acta Neurochir (Wien). 2005 Jul;147(7):721-6; discussion 726
15891808
J Clin Oncol. 1998 Nov;16(11):3563-9
9817276
Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4):797-802
8138431
J Neurosurg. 2006 Dec;105 Suppl:86-90
18503337
Cancer. 2007 Jun 15;109(12):2515-21
17487853
Acta Neurochir Suppl. 2004;91:79-87
15707029
Neurosurgery. 2003 Jun;52(6):1318-26; discussion 1326
12762877
Neurosurgery. 2007 Mar;60(3):471-81; discussion 481-2
17327791
J Neurosurg. 2005 Jan;102 Suppl:75-80
15662785
Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:41-9
9782234
Neurosurgery. 2003 May;52(5):1066-73; discussion 1073-4
12699548
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):87-93
15093903
J Neurosurg. 2000 Dec;93 Suppl 3:32-6
11143259
Neurology. 1989 Jun;39(6):789-96
2725874
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):993-9
10863070
Cancer. 2007 Jan 1;109(1):135-45
17133440
Prog Neurol Surg. 2007;20:106-128
17317980
J Clin Oncol. 1990 Apr;8(4):576-82
2179476
Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):898-903
16338097
Prog Neurol Surg. 2009;22:154-169
18948727
Int J Cancer. 2001 Jun 20;96(3):191-7
11410888
Neurol Med Chir (Tokyo). 1996 Jun;36(6):364-9
8700312
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):809-16
16682138
Neurosurgery. 2000 Aug;47(2):268-79; discussion 279-81
10942000
Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):427-34
10487566
Neurosurg Clin N Am. 1999 Apr;10(2):243-56
10099090
J Neurosurg. 2005 Jan;102 Suppl:266-71
15662823
Int J Radiat Oncol Biol Phys. 1996 Apr 1;35(1):27-35
8641923
J Neurosurg. 2002 Dec;97(5 Suppl):484-8
12507082
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1279-83
12128130
JAMA. 1998 Nov 4;280(17):1485-9
9809728
J Neurooncol. 2003 Jan;61(2):143-9
12622453